Research - Page 4 of 718 Posts on Medivizor

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Posted by Medivizor on Jun 11, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients. Some background HER2+ BC...

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

$Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.$

Posted by Medivizor on Jun 11, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of decitabine (Dacogen) combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of patients with recurrent and refractory (r/r) acute myeloid leukemia (AML). The data showed that decitabine combined with allo-HSCT reduced the risk of recurrence and improved...

Evaluating the effectiveness of progestin-primed ovarian stimulation protocol for infertile patients with different ovarian reserve functions.

Posted by Medivizor on Jun 11, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effectiveness of progestin-primed ovarian stimulation (PPOS) protocol for infertile patients with different ovarian reserve functions. The data showed that PPOS is an effective ovarian stimulation protocol and is beneficial for these patients. Some background Many couples with infertility opt to use assisted...

Does transcranial direct current stimulation improve speech production in patients with speech impairment after stroke?

Posted by Medivizor on Jun 11, 2023 in Stroke | 0 comments

In a nutshell This study evaluated the effectiveness of transcranial direct current stimulation (tDCS) on speech intelligibility, and speech-related physiological and vocal functions in dysarthric (speech impairment) patients after stroke. The data showed that tDCS enhanced the effects of traditional speech therapy in these patients. Some...

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

$Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.$

Posted by Medivizor on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Posted by Medivizor on Jun 11, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Posted by Medivizor on Jun 11, 2023 in Lung cancer | 0 comments

In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by Medivizor on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Posted by Medivizor on May 28, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients. Some...

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Posted by Medivizor on May 28, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of oral azacitidine (Onureg; Oral-AZA) maintenance treatment in older patients with acute myeloid leukemia (AML) in remission. The data showed that Oral-AZA maintenance therapy can be considered in older patients with AML for which hematopoietic stem cell transplantation (HSCT) is not an...

Can cardiovascular risk factors be reduced by consumption of soymilk and probiotics in patients with type 2 diabetes?

Posted by Medivizor on May 28, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study examined the effects of consuming soymilk and probiotics on risk factors related to heart and blood vessel diseases in patients with type 2 diabetes (T2D). The study showed that the consumption of soymilk with probiotics might improve cardiovascular (CV) risk factors in these patients. Some background T2D is a...

Research Posts on Medivizor

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

Evaluating the effectiveness of progestin-primed ovarian stimulation protocol for infertile patients with different ovarian reserve functions.

Does transcranial direct current stimulation improve speech production in patients with speech impairment after stroke?

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Can cardiovascular risk factors be reduced by consumption of soymilk and probiotics in patients with type 2 diabetes?

Categories

Recent Posts

Archives

Research Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email